Ozempic is a GLP-1 diabetes drug; Contrave is an FDA-approved weight loss pill. Ozempic (semaglutide) reduces appetite through gut-brain hormonal signaling. Contrave (naltrexone/bupropion) reduces cravings through the brain's reward pathways. For weight loss patients, the proper GLP-1 comparison is Contrave vs. Wegovy since Wegovy is the FDA-approved weight loss semaglutide.
The key difference: mechanism and target
Ozempic (semaglutide) is a GLP-1 receptor agonist FDA-approved for type 2 diabetes. It mimics a gut hormone that reduces appetite, slows gastric emptying, and improves insulin sensitivity. Weight loss is a secondary effect. Its FDA-approved weight loss counterpart is Wegovy.
Contrave (naltrexone/bupropion) is FDA-approved for chronic weight management. Naltrexone blocks the opioid reward pathways that make food feel rewarding. Bupropion is an antidepressant that suppresses appetite. Together, they target the psychological drivers of overeating — cravings, reward-seeking, and emotional eating.
Ozempic makes you less physically hungry. Contrave makes food less psychologically compelling. Different mechanisms for different drivers of weight gain.
Side-by-side comparison
| Feature | Ozempic | Contrave |
|---|---|---|
| Active ingredient | Semaglutide | Naltrexone/bupropion |
| Drug class | GLP-1 receptor agonist | Opioid antagonist + NDRI |
| FDA indication | Type 2 diabetes | Chronic weight management |
| Administration | Weekly injection | Oral tablet, twice daily |
| Avg weight loss | ~10–12% (off-label) | approximately 5–6% body weight |
| Best for | Maximum appetite suppression | Cravings-driven/emotional eating |
| CV benefit | MACE reduction (via Wegovy/SELECT) | Not established |
| Common side effects | Nausea, diarrhea, constipation | Nausea, headache, insomnia |
| Insurance for weight loss | Usually not covered (off-label) | Good; generic available |
| Cost without insurance | ~–,300/mo | ~–/mo |
| Controlled substance | No | No |
| Weight-loss version | Wegovy (semaglutide 2.4 mg) | Already approved for weight loss |
When Contrave may be the better fit
- Your weight gain is driven by emotional eating, stress eating, or food cravings rather than physical hunger
- You strongly prefer a pill over weekly injections
- You have concurrent depression (bupropion has antidepressant properties)
- Cost or insurance coverage is a primary concern (generic available)
- Your insurance requires step therapy before approving a GLP-1
- You cannot tolerate GLP-1 gastrointestinal side effects
When a GLP-1 may be the better fit
- Maximum weight loss is your primary goal
- You have cardiovascular risk factors (Wegovy has FDA-approved MACE reduction)
- You're comfortable with weekly self-injections
- Your insurance covers GLP-1 weight loss medications
- You want the metabolic benefits beyond appetite suppression (improved insulin sensitivity, reduced inflammation)
If you're comparing Ozempic and Contrave for weight loss, the fairer comparison is Contrave vs. Wegovy. Wegovy is the FDA-approved weight loss version of semaglutide. Ozempic is a diabetes medication that happens to cause weight loss. Using the correct medication for the correct indication matters for insurance coverage, clinical monitoring, and dosing.
Different tools for different patterns
The reason people search "Ozempic vs Contrave" usually comes down to wanting to know which medication will work better for them. But these two drugs address different aspects of overeating. Contrave (naltrexone/bupropion) targets the reward and craving pathways in the brain — it is most effective for patients who eat in response to stress, boredom, or emotional triggers rather than physical hunger. Semaglutide-based medications like Wegovy (the FDA-approved weight loss version of Ozempic's active ingredient) work primarily by reducing appetite and slowing gastric emptying.
In practice, the choice often depends on what is driving the weight gain. During your initial evaluation at PEAK, we assess eating patterns, metabolic labs, and medical history to determine whether a GLP-1, Contrave, or a combination approach makes the most sense. Some patients benefit from starting with Contrave while a GLP-1 prior authorization is being processed — this way treatment begins immediately rather than waiting weeks for insurance approval.
What we recommend
PEAK prescribes both Contrave and GLP-1 weight loss medications (Wegovy, Zepbound). We do not prescribe Ozempic for weight loss since FDA-approved weight loss alternatives exist.
The right medication depends on why you're gaining weight. For patients driven by cravings and food reward, Contrave's naltrexone component directly addresses that mechanism. For patients seeking maximum weight reduction and metabolic improvement, Wegovy or Zepbound provides the stronger clinical evidence.
Your clinician will evaluate your eating patterns, health history, and insurance situation to recommend the best starting point. Schedule a consultation to get started.
Boxed warning — Contrave (naltrexone/bupropion): Contrave carries an FDA boxed warning for suicidal thoughts and behaviors associated with the bupropion component. Patients should be monitored for neuropsychiatric symptoms, especially during early treatment. Contrave also increases seizure risk and should not be used with excessive alcohol consumption or abrupt discontinuation of alcohol, benzodiazepines, or antiepileptics.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
